麻豆社

Kylie Bromley was appointed Vice President and Managing Director of Biogen UK and Ireland in July 2022. 

Prior to this she held the role of Biogen鈥檚 Managing Director for Australia and New Zealand, during this role, she was elected to the Medicines Australia Board.

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient鈥檚 lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to with aspirations to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

Kylie鈥檚 background is in science, and she holds a PhD in pharmacology from the University of Melbourne. Her subsequent 20+ year career in the pharmaceutical industry has included roles across clinical research, medical affairs, commercial development, market access, sales and marketing, giving her a diverse breadth of knowledge and experience. Kylie has previously worked at Eli Lilly, Aventis and Amgen.

Kylie is passionate about improving the UK environment to ensure that patients can benefit from trials and early access to medicines in a way that is sustainable for our sector. Kylie is also co-chair of Biogen鈥檚 Global Women鈥檚 Impact Network.